Who are Azacitidine and eltrombopag's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/azacitidine-and-eltrombopag.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Azacitidine and eltrombopag — Competitive Intelligence Brief

Azacitidine and eltrombopag (Azacitidine and eltrombopag) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hypomethylating agent, Thrombopoietin receptor agonist. Area: Oncology, Hematology.

phase 2 Hypomethylating agent, Thrombopoietin receptor agonist DNA methyltransferase, Thrombopoietin receptor Oncology, Hematology Small molecule Live · refreshed every 30 min

Target snapshot

Azacitidine and eltrombopag (Azacitidine and eltrombopag) — Peter MacCallum Cancer Centre, Australia. Azacitidine is a hypomethylating agent that works by inhibiting DNA methyltransferase enzymes, leading to increased expression of tumor suppressor genes. Eltrombopag is a thrombopoietin receptor agonist that stimulates platelet production.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Azacitidine and eltrombopag TARGET	Azacitidine and eltrombopag	Peter MacCallum Cancer Centre, Australia	phase 2	Hypomethylating agent, Thrombopoietin receptor agonist	DNA methyltransferase, Thrombopoietin receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hypomethylating agent, Thrombopoietin receptor agonist class)

Peter MacCallum Cancer Centre, Australia · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Azacitidine and eltrombopag — Competitive Intelligence Brief. https://druglandscape.com/ci/azacitidine-and-eltrombopag. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab